From Endoscopic Inspection to Gene-Expression: A Thorough Assessment of the Duodenal Mucosa After Resurfacing-A Prospective Study

Overview

Journal Dig Dis Sci

Date 2025 Jan 8

PMID 39779586

Authors

S Meiring

O Aydin

A C G van Baar

E W J van der Vossen

E Rampanelli

N C T van Grieken

F Holleman

M Nieuwdorp

J J G H M Bergman

Affiliations

Soon will be listed here.

Abstract

Aims: Duodenal Mucosal Resurfacing (DMR) is an endoscopic ablation technique aimed at improving glycemia in patients with type 2 diabetes mellitus (T2DM). Although the exact underlying mechanism is still unclear, it is postulated that the DMR-induced improvements are the result of changes in the duodenal mucosa. For this reason, we assessed macroscopic and microscopic changes in the duodenal mucosa induced by DMR + GLP-1RA.

Methods: We included 16 patients with T2DM using basal insulin that received a combination treatment of a single DMR and GLP-1RA. Endoscopic evaluation was performed before the DMR procedure and 3 month after, and duodenal biopsies were obtained. Histological evaluation was performed and L and K cell density was calculated. In addition, gene-expression analysis and Western blotting was performed.

Results: Endoscopic evaluation at 3 month showed duodenal mucosa with a normal appearance. In line, microscopic histological evaluation showed no signs of villous atrophy or inflammation and unchanged L and K cell density. Unbiased transcriptome profiling and western blotting revealed that PDZK1 expression was higher in responders at baseline and after DMR. GATA6 expression was significantly increased in responders after DMR compared to non-responders.

Conclusion: The absence of macroscopic and microscopic changes after 3 month suggest that improvements in glycemic parameters after DMR do not result from significant histological changes in duodenal mucosa. It is more likely that these improvements result from more subtle changes in enteroendocrine signaling. PDZK1 and GATA6 expression might play a role in DMR; this needs to be confirmed in pre-clinical studies.

References

Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G . Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015; 386(9997):964-73. DOI: 10.1016/S0140-6736(15)00075-6. View

Cani P, Amar J, Iglesias M, Poggi M, Knauf C, Bastelica D . Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56(7):1761-72. DOI: 10.2337/db06-1491. View

van Baar A, Nieuwdorp M, Holleman F, Soeters M, Groen A, Bergman J . The Duodenum harbors a Broad Untapped Therapeutic Potential. Gastroenterology. 2018; 154(4):773-777. DOI: 10.1053/j.gastro.2018.02.010. View

Nauck M, Bartels E, Orskov C, Ebert R, Creutzfeldt W . Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 1993; 76(4):912-7. DOI: 10.1210/jcem.76.4.8473405. View

Meier J, Gallwitz B, Siepmann N, Holst J, Deacon C, Schmidt W . Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia. 2003; 46(6):798-801. DOI: 10.1007/s00125-003-1103-y. View

Elrick H, STIMMLER L, HLAD Jr C, Arai Y . PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. J Clin Endocrinol Metab. 1964; 24:1076-82. DOI: 10.1210/jcem-24-10-1076. View

Turton M, OShea D, Gunn I, Beak S, Edwards C, Meeran K . A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996; 379(6560):69-72. DOI: 10.1038/379069a0. View

Flint A, Raben A, Astrup A, Holst J . Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998; 101(3):515-20. PMC: 508592. DOI: 10.1172/JCI990. View

Van Der Schueren B, Homel P, Alam M, Agenor K, Wang G, Reilly D . Magnitude and variability of the glucagon-like peptide-1 response in patients with type 2 diabetes up to 2 years following gastric bypass surgery. Diabetes Care. 2011; 35(1):42-6. PMC: 3241324. DOI: 10.2337/dc11-1472. View

10.

Holter M, Dutia R, Stano S, Prigeon R, Homel P, McGinty Jr J . Glucose Metabolism After Gastric Banding and Gastric Bypass in Individuals With Type 2 Diabetes: Weight Loss Effect. Diabetes Care. 2016; 40(1):7-15. PMC: 5180462. DOI: 10.2337/dc16-1376. View

11.

Lund M, Hansen M, Skaaby S, Dalby S, Stockel M, Floyd A . Preoperative β-cell function in patients with type 2 diabetes is important for the outcome of Roux-en-Y gastric bypass surgery. J Physiol. 2015; 593(14):3123-33. PMC: 4532531. DOI: 10.1113/JP270264. View

12.

Laferrere B, Teixeira J, Mcginty J, Tran H, Egger J, Colarusso A . Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008; 93(7):2479-85. PMC: 2453054. DOI: 10.1210/jc.2007-2851. View

13.

Purnell J, Johnson G, Wahed A, Dalla Man C, Piccinini F, Cobelli C . Prospective evaluation of insulin and incretin dynamics in obese adults with and without diabetes for 2 years after Roux-en-Y gastric bypass. Diabetologia. 2018; 61(5):1142-1154. PMC: 6634312. DOI: 10.1007/s00125-018-4553-y. View

14.

Rajagopalan H, Cherrington A, Thompson C, Kaplan L, Rubino F, Mingrone G . Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study. Diabetes Care. 2016; 39(12):2254-2261. DOI: 10.2337/dc16-0383. View

15.

McDermaid A, Monier B, Zhao J, Liu B, Ma Q . Interpretation of differential gene expression results of RNA-seq data: review and integration. Brief Bioinform. 2018; 20(6):2044-2054. PMC: 6954399. DOI: 10.1093/bib/bby067. View

16.

Crow M, Lim N, Ballouz S, Pavlidis P, Gillis J . Predictability of human differential gene expression. Proc Natl Acad Sci U S A. 2019; 116(13):6491-6500. PMC: 6442595. DOI: 10.1073/pnas.1802973116. View

17.

Chen M, Lu X, Lu C, Shen N, Jiang Y, Chen M . Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K/Akt signaling pathway. Arthritis Res Ther. 2018; 20(1):20. PMC: 5803867. DOI: 10.1186/s13075-018-1512-4. View

18.

Tofe S, Arguelles I, Mena E, Serra G, Codina M, Urgeles J . Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study. Endocrinol Diabetes Metab. 2019; 2(1):e00051. PMC: 6354754. DOI: 10.1002/edm2.51. View

19.

Udayappan S, Kovatcheva-Datchary P, Bakker G, Havik S, Herrema H, Cani P . Intestinal Ralstonia pickettii augments glucose intolerance in obesity. PLoS One. 2017; 12(11):e0181693. PMC: 5699813. DOI: 10.1371/journal.pone.0181693. View

20.

Maassen J, Romijn J, Heine R . Fatty acid-induced mitochondrial uncoupling in adipocytes as a key protective factor against insulin resistance and beta cell dysfunction: a new concept in the pathogenesis of obesity-associated type 2 diabetes mellitus. Diabetologia. 2007; 50(10):2036-41. PMC: 2039833. DOI: 10.1007/s00125-007-0776-z. View